INmune Bio and Quantum Computing Inc. team up to use quantum computing for new drug treatment discoveries.

INmune Bio and Quantum Computing Inc. have partnered to apply quantum computing, AI, and data analytics to identify new treatment uses and biomarkers for INmune Bio's drug candidate XPro, aimed at Alzheimer's and other diseases. This collaboration leverages INmune Bio's clinical data and QCi's Dirac-3S quantum optimization machine to uncover disease targets sharing XPro's biology, prioritizing those with high success potential. This marks QCi's first commercial engagement in pharma, aiming to enhance drug development efficiency and explore quantum computing's practical benefits in biomedical research. The partnership will also compare quantum methods with traditional analytics to establish a repeatable discovery process for future studies.

Quantum Computing Inc. (QUBT) shares trade at USD 6.84 on Pluang as of Oct 14, 2026 19:13 WIB, down 0.44% in the last day. The stock's market cap stands at $1.56 billion, reflecting significant investor interest in its technology sector role. This partnership news arrives while QUBT maintains a 57% buy order activity on Pluang, indicating ongoing demand for the stock.